EUCTR2010-019085-82-DE进行中（未招募）不适用
A PHASE II, DOUBLE BLIND, RANDOMISED, PLACEBO AND ACTIVE COMPARATOR CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF THREE DOSES OF DYSPORT RU (20 U, 50 U AND 75 U) ADMINISTERED AS A SINGLE TREATMENT CYCLE TO IMPROVE THE APPEARANCE OF MODERATE TO SEVERE GLABELLAR LINES
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 160
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •(1) Provision of written informed consent prior to any study related procedures. (2) Be female between 30 and 60 years of age, inclusive. (3) Have moderate to severe vertical glabellar lines at maximum frown at Day 1 (baseline, pre-treatment), as assessed by the Investigator’s and subject’s assessment using a validated 4-point Photographic Scale. (4) Be naïve to previous treatment with any serotype of BTX. (5) Have a negative pregnancy test (for females of childbearing potential only). Nonchildbearing potential is defined as post-menopausal for at least 1 year, surgical sterilisation at least three months before entering screening, or hysterectomy. (6) Have both the time and ability to complete the study and comply with study instructions. (7) Have an understanding of the study and the contents of the informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 160
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 0
排除标准
- •(1) Previous treatment with any serotype of BTX. (2) A history of silicone injections into upper face within the previous 5 years. (3) Any prior treatment with permanent or semi-permanent dermal fillers in the glabellar region within the previous 5 years and/or skin abrasions or photorejuvenation within the previous 12 months. (4) Any planned facial cosmetic surgery during the study period. (5) A history of ablative skin resurfacing of the area to be treated during the study. (6) A history of upper eyelid blepharoplasty or brow lift within the previous 5 years. (7) An inability to substantially reduce glabellar lines by physically spreading them apart. (8) An active infection or other skin problem in the glabellar area (e.g. acute acne lesions or ulcers). (9) Concurrent therapy which, in the Investigator’s opinion, would interfere with the evaluation of the safety or efficacy of the study treatment. (10) Pregnant women, nursing mothers, or women who are planning a pregnancy during the study, or think they may be pregnant at the start of the study. Throughout the course of the study, women of childbearing potential must use a reliable form of contraception (e.g. oral contraceptives for more than 12 consecutive weeks, or spermicide and condoms). (11) A history of chronic drug or alcohol abuse. (12) Receipt of any experimental drug or use of any experimental device within 30 days prior to the start of the study and during the conduct of the study. (13) Known allergy or hypersensitivity to any serotype of BTX or any component of Dysport RU or Dysport. (14) Clinically diagnosed anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the subject’s participation in the study. (15) Use of medications that affect neuromuscular transmission, such as curare-like nondepolarizing agents, lincosamides, polymyxins, anticholinesterases and aminoglycoside antibiotics. (16) A history of facial nerve palsy. (17) Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin. (18) Presence of any other condition (e.g. neuromuscular disorder or other disorder that could interfere with neuromuscular function), laboratory finding or circumstance that, in the judgment of the Investigator, might increase the risk to the subject or decrease the chance of obtaining satisfactory data to achieve the objectives of the study.
研究者
相似试验
进行中（未招募）
1 期
Study to assess the effect of RPL554 compared to placebo when given in addition to TIOTROPIUM/OLODATEROL in patients with moderate to severe COPDChronic Obstructive Pulmonary Disease (COPD)MedDRA version: 20.0 Level: PT Classification code 10009033 Term: Chronic obstructive pulmonary disease System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2018-001037-41-GBVerona Pharma plc79
进行中（未招募）
1 期
A Study to Assess the Efficacy and Safety of MSTT1041A in Patients with Moderate to Severe Atopic DermatitisEUCTR2018-003429-27-DEGenentech Inc.65
未知
不适用
A PHASE II/III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP TRIAL TO EVALUATE SAFETY AND EFFICACY OF TIOTORPIUM INHALATION SOLUTION (2.5 µG AND 5µG) ADMINISTERED ONCE DAILY IN THE AFTERNOON VIA RESPIMAT® INHALER FOR 12 WEEKS INPATIENTS 1 TO 5 YEARS OLD WITH PERSISTENT ASTHMA.PER-077-12Boehringer Ingelheim,
进行中（未招募）
1 期
A Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Patients with Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer.on-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10079440Term: Non-squamous non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-002851-39-ITF. HOFFMANN - LA ROCHE LTD.200
进行中（未招募）
1 期
A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals with Prodromal and Early Manifest Huntington’s DiseaseHuntington's disease (HD)MedDRA version: 20.0Level: PTClassification code 10070668Term: Huntington's diseaseSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2022-001991-32-ATF.Hoffmann-La Roche Ltd300